cervical cancer
Conditions
Interventions
Case series:None
Sponsors
The First Affiliated Hospital of University of Science and Technology of China
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged at least 18 years; 2. Cervical HPV infection or histopathological examination confirmed as cervical precancerous lesions or cervical cancer; 3. Patients with cervical cancer evaluated by researchers need to accept and tolerate conventional first-line chemotherapy, or need to receive second-line or multi-line chemotherapy after first-line treatment failure; 4. Participate in the clinical study voluntarily, cooperate with the investigator to carry out the study, and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. There are known contraindications to the upcoming first-line chemotherapy or second-line or multi-line chemotherapy; 2. Persons with the following active infectious diseases, including active tuberculosis, hepatitis, syphilis, known human immunodeficiency virus (HIV) infection, etc. Combined with neurological or mental disorders and unable to cooperate or unwilling to cooperate; 3. Past medical history indicated serious comorbidities: severe chronic obstructive pulmonary disease with hypoxemia; Uncontrolled hypertension, cerebrovascular accident/stroke, myocardial infarction, unstable angina, thrombosis, chronic congestive heart failure, or severe arrhythmia requiring medication; A history of severe hepatitis or liver disease; Nephrotic syndrome, renal insufficiency; History of active ulcers, abdominal wall fistula, gastrointestinal perforation, or intraperitoneal abscesses; Uncontrolled diabetes; Uncontrolled epilepsy requiring long-term anticonvulsant therapy. 4. Appropriate organ functions are excluded from the group if: (1) Absolute neutrophil count (ANC) = 1.0g/24h; (6) Partial prothrombin time (APTT) and prothrombin time (PT) exceeded 1.5 x ULN (based on the normal value of clinical trial research center); 5. The investigator considers that the subject is not suitable to participate in the clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CA125;SCC; | — |
Countries
China
Contacts
Public ContactZhou Ying
Outcome results
None listed